Fortitude Family Office, LLC
Family OfficePosition in DNLI — Denali Therapeutics Inc.
CIK 1950506
SCOTTSDALE, AZ
Position in DNLI
as of Jun 30, 2026
· filed Jul 20, 2026
Position Value
$1,568
+$896 QoQ
Shares Held
61
+74.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#259
of 290 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNLI Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Fortitude Family Office, LLC holds $736,227 across 148 Biotechnology names. DNLI ranks #68 (0.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
523 | $157,438 | |
| 2 | INCY |
Incyte Corp
|
641 | $72,663 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
292 | $54,685 | |
| 4 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
72 | $35,764 | |
| 5 | JAZZ |
Jazz Pharmaceuticals plc
|
128 | $30,844 | |
| 6 | FTRE |
Fortrea Holdings Inc.
|
1,647 | $28,657 | |
| 7 | RLAY |
Relay Therapeutics, Inc.
|
1,268 | $23,724 | |
| 8 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
228 | $18,584 |
All Filings in DNLI
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,568 | 61 | Shares | Sole | 2026-07-20 | |
| 2026-03-31 | $672 | 35 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $115 | 7 | Shares | Sole | 2026-01-15 | |
| 2025-09-30 | $130 | 9 | Shares | Sole | 2025-10-17 | |
| 2025-06-30 | $573 | 41 | Shares | Sole | 2025-07-15 | |
| No filing history on record for this holder in this stock. | ||||||